comparemela.com

Latest Breaking News On - Gastrointestinal oncology service - Page 1 : comparemela.com

First Patient Dosed With Drug Combo in Phase 2 Gastric Cancer Trial

Imfinzi, Chemo Improves Outcomes in GI Cancers, Regardless of Region

Imfinzi plus chemotherapy, when given before surgery, improved pathologic complete response rates, regardless of region, in certain patients with gastric or gastroesophageal junction cancers.

Neoadjuvant Durvalumab Plus Chemo Boosts pCR Vs Chemo Alone in Gastric/GEJ Cancers Regardless of Region

Dr Shiu on the FDA Approval of Pembrolizumab Plus Chemotherapy in Advanced HER2– Gastric/GEJ Adenocarcinoma

Kai-Keen Shiu, MD, discusses the significance of the FDA approval of pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment in patients with locally advanced, unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Domvanalimab Plus Zimberelimab and Chemotherapy Elicits Responses in Advanced Gastric/GEJ Adenocarcinoma

The combination of domvanalimab, zimberelimab, and FOLFOX elicited responses in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, irrespective of PD-L1 status

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.